image
Healthcare - Biotechnology - NASDAQ - US
$ 0.607
-1.14 %
$ 50.2 M
Market Cap
-0.47
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ACET stock under the worst case scenario is HIDDEN Compared to the current market price of 0.607 USD, Adicet Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ACET stock under the base case scenario is HIDDEN Compared to the current market price of 0.607 USD, Adicet Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one ACET stock under the best case scenario is HIDDEN Compared to the current market price of 0.607 USD, Adicet Bio, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ACET

image
$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.415 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
-128 M OPERATING INCOME
16.06%
-117 M NET INCOME
17.90%
-92.4 M OPERATING CASH FLOW
1.43%
-119 M INVESTING CASH FLOW
-2571.19%
111 M FINANCING CASH FLOW
47063.98%
0 REVENUE
0.00%
-29.9 M OPERATING INCOME
2.79%
-28.2 M NET INCOME
1.79%
-25.4 M OPERATING CASH FLOW
-5.38%
-2.86 M INVESTING CASH FLOW
87.07%
-104 K FINANCING CASH FLOW
-75.91%
Balance Sheet Adicet Bio, Inc.
image
Current Assets 180 M
Cash & Short-Term Investments 176 M
Receivables 0
Other Current Assets 3.83 M
Non-Current Assets 40.1 M
Long-Term Investments 0
PP&E 36.8 M
Other Non-Current Assets 3.33 M
80.06 %16.69 %Total Assets$220.2m
Current Liabilities 19.4 M
Accounts Payable 4.83 M
Short-Term Debt 3.13 M
Other Current Liabilities 11.4 M
Non-Current Liabilities 14.2 M
Long-Term Debt 14.1 M
Other Non-Current Liabilities 116 K
14.37 %9.32 %34.01 %41.96 %Total Liabilities$33.6m
EFFICIENCY
Earnings Waterfall Adicet Bio, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 128 M
Operating Income -128 M
Other Expenses -10.5 M
Net Income -117 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)000(128m)(128m)10m(117m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-62.76% ROE
-62.76%
-53.18% ROA
-53.18%
-62.57% ROIC
-62.57%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Adicet Bio, Inc.
image
40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -117 M
Depreciation & Amortization 6.47 M
Capital Expenditures -1.12 M
Stock-Based Compensation 22.2 M
Change in Working Capital -5.52 M
Others -5.06 M
Free Cash Flow -93.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Adicet Bio, Inc.
image
ACET has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.01 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.3000.3000.2500.2500.2000.2000.1500.1500.1000.1000.0500.0500.0000.0000.060.060.0650.0650.060.060.0650.010.060.0650.0650.010.060.240.0650.250.0650.260.0820152015201620162017201720182018
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Adicet Bio, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 3-5, 2025 in New York. Details of the event are as follows: Date: Wednesday, June 4, 2025 Time: 4:20. businesswire.com - 1 month ago
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 1 month ago
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2025. “We are approaching an exciting inflection point for our pipeline, with significant data milestones on the horizon,” said Chen Schor, President and Chief Executive Officer. businesswire.com - 2 months ago
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on April 30, 2025. Three individuals were hired by Adicet in April 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 206,800 shares of Adicet's common stock with an exercise price of $0.66 per. businesswire.com - 2 months ago
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of an abstract for an oral presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place May 13-17, 2025, in New Orleans, LA. Details of the oral presentation are as follows: Title: ADI-270, an Armo. businesswire.com - 2 months ago
Adicet Bio Appoints Michael Grissinger to the Board of Directors REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. “We are honored to welcome Michael t. businesswire.com - 2 months ago
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on March 31, 2025. Two individuals were hired by Adicet in March 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 38,600 shares of Adicet's common stock with an exercise price of $0.76 per sh. businesswire.com - 3 months ago
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025. Details of the event are as follows: Panel: “CAR T Approaches in the Autoimmune Space. businesswire.com - 3 months ago
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2024. “In 2025 we plan to continue advancing our gamma delta 1 CAR T cell therapy programs, achieving key milestones and reporting preliminary data in autoimmune and. businesswire.com - 4 months ago
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A. Details of the poster presentation are as follows: Abstract Ti. businesswire.com - 4 months ago
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with refractory systemic lupus erythematosus (SLE) with extrarenal involvement. Fast Track Designation is a process designed. businesswire.com - 5 months ago
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on January 31, 2025. Two individuals were hired by Adicet in January 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 28,600 shares of Adicet's common stock with an exercise price of $0.89 pe. businesswire.com - 5 months ago
8. Profile Summary

Adicet Bio, Inc. ACET

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 50.2 M
Dividend Yield 0.00%
Description Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Contact 200 Clarendon Street, Boston, MA, 02116 https://www.adicetbio.com
IPO Date Jan. 26, 2018
Employees 152
Officers Ms. Amy Locke Chief Human Resource Officer Dr. Blake Aftab Ph.D. Senior Vice President & Chief Scientific Officer Dr. Aya Jakobovits Ph.D. Founder & Independent Director Mr. Brian Nicholas Harvey Chief Financial Officer Mr. Chen Schor BA, CPA, M.B.A. Chief Executive Officer, President & Director Dr. Donald Healey Ph.D. Chief Technology Officer Dr. Julie Maltzman M.D. Chief Medical Officer